<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
      <PMID Version="1">35377276</PMID>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>23</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1744-8409</ISSN>
          <JournalIssue CitedMedium="Internet">
            <PubDate>
              <Year>2022</Year>
              <Month>May</Month>
              <Day>04</Day>
            </PubDate>
          </JournalIssue>
          <Title>Expert review of clinical immunology</Title>
          <ISOAbbreviation>Expert Rev Clin Immunol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>The suitability of treating atopic dermatitis with Janus kinase inhibitors.</ArticleTitle>
        <Pagination>
          <StartPage>1</StartPage>
          <EndPage>21</EndPage>
          <MedlinePgn>1-21</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1080/1744666X.2022.2060822</ELocationID>
        <Abstract>
          <AbstractText Label="INTRODUCTION" NlmCategory="UNASSIGNED">Atopic dermatitis (AD) is a chronic inflammatory skin disease with significant morbidity and reduced quality of life, especially in patients with moderate-severe AD. Recently, topical and oral Janus kinase (JAK)-inhibitors were investigated as treatments for mild-moderate and moderate-severe AD. However, rare serious adverse-events observed with JAK-inhibitor therapy in AD, rheumatoid arthritis, and other immune-mediated disorders warrant careful consideration.</AbstractText>
          <AbstractText Label="AREAS COVERED" NlmCategory="UNASSIGNED">This review examines the efficacy and safety of topical and oral JAK-inhibitors for treatments in AD, and reviews potential applications in AD.</AbstractText>
          <AbstractText Label="EXPERT OPINION" NlmCategory="UNASSIGNED">JAK-inhibitors have rapid-onset and robust and durable efficacy, which give them considerable versatility for treating the gamut of AD patients. While the U.S. Food and Drug Administration has only approved upadacitinib and abrocitinib to treat moderate-severe AD refractory to treatment with other systemic medications including biologics, or when use of those therapies is not recommended, oral JAK-inhibitors have the potential to be used both as first-line or second-line systemic therapies in moderate-severe AD. However, oral JAK-inhibitors can lead to laboratory anomalies and rare serious adverse events. All of these important characteristics should be addressed in shared-decision-making conversations, patient counseling, choosing appropriate therapies for patients, and monitoring patients in clinical practice.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Narla</LastName>
            <ForeName>Shanthi</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Dermatology, St. Luke's University Health Network, Easton, Pennsylvania, United States.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Silverberg</LastName>
            <ForeName>Jonathan I</ForeName>
            <Initials>JI</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Dermatology, The George Washington University School of Medicine and Health Sciences, Washington, DC, United States.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>05</Month>
          <Day>04</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>England</Country>
        <MedlineTA>Expert Rev Clin Immunol</MedlineTA>
        <NlmUniqueID>101271248</NlmUniqueID>
        <ISSNLinking>1744-666X</ISSNLinking>
      </MedlineJournalInfo>
      <CitationSubset>IM</CitationSubset>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Atopic dermatitis</Keyword>
        <Keyword MajorTopicYN="N">abrocitinib</Keyword>
        <Keyword MajorTopicYN="N">adverse-events</Keyword>
        <Keyword MajorTopicYN="N">baricitinib</Keyword>
        <Keyword MajorTopicYN="N">janus kinase inhibitors</Keyword>
        <Keyword MajorTopicYN="N">ruxolitinib</Keyword>
        <Keyword MajorTopicYN="N">safety</Keyword>
        <Keyword MajorTopicYN="N">upadacitinib</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>5</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>5</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>4</Day>
          <Hour>12</Hour>
          <Minute>14</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>aheadofprint</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35377276</ArticleId>
        <ArticleId IdType="doi">10.1080/1744666X.2022.2060822</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
